Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.31 |
| ▸ | HSD17B4 | P51659 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103257 | 0.87 | RBP4 (0.35) | PGR | |
| SCHEMBL4521267 | 0.81 | ROCK2 (0.37) | — | |
| SCHEMBL4521626 | 0.80 | SLC6A2 (0.30) | — | |
| SCHEMBL4516883 | 0.80 | CHRNA7 (0.39) | — | |
| SCHEMBL3965157 | 0.80 | — | — | |
| SCHEMBL4511597 | 0.79 | PGR (0.35) | HSD17B1HSD17B2HSD17B4PGR | |
| SCHEMBL4517423 | 0.78 | OPRM1 (0.37) | — | |
| SCHEMBL4511694 | 0.78 | OPRM1 (0.35) | — | |
| SCHEMBL27706480 | 0.78 | CHRM2 (0.31) | — | |
| SCHEMBL5094787 | 0.78 | NISCH (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| EP-1833825-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069277-A1 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135524-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | PRCP 1366/4885HSD17B1 769/4885HSD17B2 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.